Compare IDEXX Laboratories, Inc. (IDXX) vs JBS N.V. Class A Common Shares (JBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs JBS N.V. Class A Common Shares — how do they compare? IDEXX Laboratories, Inc. trades at $532.96 (market cap $41.68B), while JBS N.V. Class A Common Shares trades at $13 (market cap $13.96B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3× JBS N.V. Class A Common Shares's market cap, and JBS N.V. Class A Common Shares pays a 10.31% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 47 Days and JBS N.V. Class A Common Shares for 0 Days on average.
| IDXX | JBS | |
|---|---|---|
Market Cap | $41.68B | $13.96B |
Volume | 824,427 | 5,326,589 |
Sector | Health | Consumer Staples |
52-Week High | $766.68 | $18.42 |
52-Week Low | $504.70 | $10.86 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | $42.58B | $34.93B |
Dividend Yield | — | 10.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $520.31, down 0.69% with neutral technical signals. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $4.27 versus $3.94, maintaining a 3-quarter beat streak. Revenue growth accelerated to $4.3B in 2025 with robust 25.03% net margins and exceptional 74.21% ROE. Recent acquisitions like CoVetAI expand veterinary workflow capabilities while management reaffirmed long-term growth targets at the Morgan Stanley Healthcare Conference.
Wall Street maintains bullish sentiment with 56.5% buy ratings and $665 consensus target implying 28% upside. Strong profitability and diagnostic innovation pipeline support growth, though elevated P/E of 37.2 and recent insider selling pose valuation concerns. Key risks include FX headwinds, weaker U.S. vet visits, and competitive pressures in veterinary diagnostics.
JBS trades at $12.93, up 0.54% today, with a neutral technical signal and strong analyst buy consensus. The stock shows attractive valuation with a P/E of 12.08 and P/S of 0.47, though recent quarterly EPS misses and a declining profit margin to 1.22% in 2026 highlight earnings pressure. Recent news includes a proposal to acquire full control of Pilgrim's Pride and a joint venture in Southeast Asia, indicating strategic expansion.
The outlook is mixed: analyst targets suggest ~40% upside to $18.17, but risks include execution on acquisitions, margin compression, and volatile beef markets. Cash flow turned positive in 2026 projections, supporting growth initiatives, yet debt levels and competitive pressures warrant caution for investors seeking stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About JBS N.V. Class A Common Shares
JBS N.V. is a protein-processing company producing beef, pork, poultry, lamb, fish, and plant-based products, headquartered in São Paulo and Amsterdam. It operates more than 250 production facilities across over 16 countries under brands including Friboi, Seara, Swift, and Pilgrim's, and is the majority shareholder of Pilgrim's Pride Corporation.
Read more on JBS →
